CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
CG Oncology (NASDAQ: CGON) said its CEO Arthur Kuan and President & COO Ambaw Bellete will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 8:15 am PT / 11:15 am ET at the Westin St. Francis in San Francisco.
Investors can listen via a live audio webcast accessible from the company's Investor Relations website at www.cgoncology.com. A replay will be posted shortly after the presentation and archived for about 90 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CGON gained 0.82%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: CELC +3.23%, IBRX +1.46%, LQDA +2.52%, TARS -0.47%, FOLD 0%, while CGON was down 4.19%, suggesting stock-specific pressure rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Research fellowship | Positive | +1.7% | Announced second annual NMIBC research fellowship with two $50,000 grants. |
| Dec 05 | Clinical data update | Positive | -3.7% | Reported promising cretostimogene efficacy and tolerability in BOND-003 and CORE-008. |
| Nov 26 | Board/BLA update | Positive | -1.5% | Added new director and noted initiation of BLA for cretostimogene. |
| Nov 25 | Conference presentation | Positive | -1.5% | Planned late-breaking SUO presentations and posters on cretostimogene trials. |
| Nov 14 | Earnings/business update | Positive | +8.6% | Q3 2025 results, strong cash of $680.3M, BLA progress and Phase 3 enrollment. |
Recent news often positive, but price reactions have been mixed, with notable divergence on clinical and governance updates and stronger alignment on earnings.
Over the last few months, CG Oncology reported multiple milestones, including Q3 2025 results with cash of $680.3M and progress on a rolling BLA, early completion of the Phase 3 PIVOT-006 trial, and strong BOND-003 efficacy data. The stock rallied 8.61% on earnings but fell after positive clinical and board updates, indicating uneven reactions. The current J.P. Morgan conference appearance continues a pattern of active scientific and investor engagement rather than a discrete clinical or financial catalyst.
Market Pulse Summary
This announcement highlights CG Oncology’s participation in a major industry event, with management presenting at the J.P. Morgan Healthcare Conference on January 15, 2026. It extends a pattern of active communication following recent clinical data, board changes, and a solid Q3 cash position of $680.3M. Investors may focus on any incremental color provided during the presentation regarding BLA progress, Phase 3 timelines, and commercial readiness for cretostimogene.
AI-generated analysis. Not financial advice.
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:15 am PT / 11:15 am ET. The conference is taking place at the Westin St. Francis San Francisco, California.
Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com
FAQ
When will CG Oncology (CGON) present at the J.P. Morgan Healthcare Conference in 2026?
Who will represent CG Oncology (CGON) at the January 15, 2026 presentation?
How can investors access the CG Oncology (CGON) live webcast on January 15, 2026?
Will CG Oncology (CGON) provide a replay of its January 15, 2026 presentation?
What topics will CG Oncology (CGON) likely cover at the J.P. Morgan Healthcare Conference?
Where is the 44th Annual J.P. Morgan Healthcare Conference being held for CG Oncology's (CGON) presentation?
